NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Exela Pharma Sciences

Exela Pharma Sciences

Private
Lenoir, North CarolinaHealthcare & Life Scienceshttps://exelapharma.com/

Last Round

Grant

Dec 22, 2022

Total Funding Raised

$87.83M

Company Overview

Exela Pharma Sciences is a pharmaceutical company that develops, manufactures, and markets proprietary and generic sterile injectable products.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Hardware Sales

AI Layer

Non-AI

Keywords

sterile injectablesCDMOcontract manufacturinggeneric pharmaceuticalsfill-finishdrug manufacturingcritical care medicationspharmaceutical supply chaindrug shortage solutionsdomestic manufacturinginjectable drugspharma outsourcingANDA developmentFDA inspected facilitiespharmaceutical recall

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exela Pharma Sciences Comparables

Compare Exela Pharma Sciences with similar companies based on industry and business-model similarity.

Exela Pharma Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SCA Pharma
85%
Sagent Pharmaceuticals
84%
Nephron Pharmaceuticals Corporation
81%

Exela Pharma Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 22, 2022
GrantMay 5, 2022
DebtOct 1, 2021
DebtJul 24, 2013
GrantJan 3, 2013
Series A
Jul 1, 2008

Exela Pharma Sciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 17, 2025

    Company requests new trial for patent infringement allegations.

  • Dec 22, 2022

    $2M grant from the Administration for Strategic Preparedness and Response.

Exela Pharma Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Exela Pharma Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Exela Pharma Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersLenoir, North Carolina
Employee Range349
Year Founded2005
Last FundingDec 22, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.